LDHA and breast cancer: Thus, therapies eliminating ALDH+, CD44+/CD24− and ALDH+/CD44+/CD24− cells may represent a new approach for the clinical management of triple-negative basal-like mesenchymal breast cancer, currently the only major breast tumor subtype without effective targeted treatment strategies and with poor prognosis [32].